Another open-label study on 14 insulin-resistant obese adults diagnosed as established T1D patients (no autoantibody or C-peptide data are available) treated with anakinra for 1 week showed a significant decrease in glucose levels (P < .01), improved insulin sensitivity weeks posttreatment (P = .02), and reduction of HbA1c (P < .01; van Asseldonk et al, 2015). This evidence concerns the gene INS and type 1 diabetes mellitus.